Singapore legislation
Regulation 51
of Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021
Regulation 51
Duty to carry out risk management plan
Subregulation 1
The Authority may, for the purposes of minimising risks relating to unsafe and inefficacious use of CTGT products, direct a registrant of a CTGT product to implement a risk management plan which includes, but is not limited to, the following:
producing and distributing educational material;
producing and distributing safety information;
performing clinical studies of the CTGT product;
implementing active surveillance programmes of the CTGT product;
implementing programmes to restrict the supply of the CTGT product.
Subregulation 2
A registrant of a CTGT product who fails to comply with a direction of the Authority under paragraph (1) shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $10,000 or to imprisonment for a term not exceeding 6 months or to both.